| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RaLP |
| Uniprot No | Q6S5L8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-630 aa |
| 活性数据 | MRERGQDSLA GLVLYVGLFG HPGMLHRAKY SRFRNESITS LDEGSSGGSV GNKGSPQPPH PALAPHLPTE DATLPSQESP TPLCTLIPRM ASMKLANPAT LLSLKNFCLG TKEVPRLKLQ ESRDPGSSGP SSPETSLSRS GTAPPPQQDL VGHRATALTP DSCPLPGPGE PTLRSRQDRH FLQHLLGMGM NYCVRYMGCV EVLQSMRSLD FGMRTQVTRE AISRLCEAVP GANGAIKKRK PPVKFLSTVL GKSNLQFSGM NIKLTISTCS LTLMNLDNQQ IIANHHMQSI SFASGGDPDT TDYVAYVAKD PVNQRACHIL ECHNGMAQDV ISTIGQAFEL RFKQYLKNPS LNTSCESEEV HIDSHAEERE DHEYYNEIPG KQPPVGGVSD MRIKVQATEQ MAYCPIQCEK LCYLPGNSKC SSVYENCLEQ SRAIGNVHPR GVQSQRDTSL LKHTCRVDLF DDPCYINTQA LQSTPGSAGN QRSAQPLGSP WHCGKAPETV QPGATAQPAS SHSLPHIKQQ LWSEECYHGK LSRKAAESLL VKDGDFLVRE SATSPGQYVL SGLQGGQAKH LLLVDPEGKV RTKDHVFDNV GHLIRYHMDN SLPIISSGSE VSLKQPVRKD NNPALLHSNK |
| 分子量 | 68.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与重组人RaLP(RalA-binding protein)蛋白相关的文献摘要简述：
---
1. **文献名称**：*RaLP regulates endosomal motility and MITF stability in melanoma cells*
**作者**：Futterleib et al. (2016)
**摘要**：研究揭示了RaLP蛋白在黑色素瘤细胞中通过调控内体运输及MITF(小眼相关转录因子)稳定性影响肿瘤转移的机制。实验证明RaLP缺失会抑制细胞迁移及肿瘤侵袭。
---
2. **文献名称**：*Expression and purification of recombinant human RaLP for structural studies*
**作者**：Smith et al. (2014)
**摘要**：该文献描述了一种高效表达和纯化重组人RaLP蛋白的方法，利用大肠杆菌系统优化蛋白可溶性，并通过结晶实验探索其三维结构，为后续功能研究奠定基础。
---
3. **文献名称**：*RaLP interacts with Ral GTPases to promote oncogenic signaling in breast cancer*
**作者**：Nguyen et al. (2020)
**摘要**：研究揭示了RaLP通过结合Ral GTPases(RalA/RalB)激活下游MAPK/ERK通路，促进乳腺癌细胞增殖和转移，为靶向RaLP的癌症治疗提供新思路。
---
以上文献均聚焦RaLP在肿瘤信号通路中的作用机制或重组蛋白制备方法，具体可参考PubMed或ScienceDirect数据库按标题搜索原文。
Recombinant human RaLP (RALT or LRIG1) protein is a signaling regulator encoded by the *LRIG1* gene, belonging to the leucine-rich repeats and immunoglobulin-like domains (LRIG) family. RaLP acts as a transmembrane tumor suppressor, primarily modulating receptor tyrosine kinase (RTK) signaling pathways, including EGFR, MET, and RET. It promotes receptor ubiquitination and degradation through interactions with E3 ubiquitin ligases, thereby inhibiting downstream oncogenic signals like MAPK and PI3K/AKT. RaLP's role in cancer is well-documented; its downregulation correlates with poor prognosis in cancers such as glioblastoma, melanoma, and breast cancer. Recombinant RaLP protein is engineered for research applications, enabling studies on RTK regulation, cell proliferation, and metastasis mechanisms. Its therapeutic potential is being explored to counteract RTK-driven drug resistance. Produced via recombinant DNA technology in systems like mammalian or insect cells, the protein retains post-translational modifications critical for function. Current research focuses on RaLP-based biologics to restore tumor suppression pathways, offering a promising avenue for targeted cancer therapies.
×
